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Long peptide immunization is a promising strategy to clear established tumors. In the current study, we
investigated the therapeutic effect of a naturally existing long peptide that contained two HLA-A2.1
restricted epitopes (CRPVE1/149–157 and CRPVE1/161–169) from cottontail rabbit papillomavirus
(CRPV) E1 using our CRPV/HLA-A2.1 transgenic rabbit model. A universal Tetanus Toxin helper motif
(TT helper) was tagged at either the N-terminus or the carboxyl-terminus of this long peptide and des-
ignated as TT-E1 peptide and E1 peptide-TT, respectively. Four groups of HLA-A2.1 transgenic rabbits
were infected with wild type CRPV DNA. Three weeks post-infection, the rabbits were immunized four
times with TT-E1 peptide, E1 peptide only, E1 peptide-TT or TT-control peptide with two-week intervals
between immunizations. Tumor outgrowth was monitored and recorded weekly. After the third booster
immunization, tumors on two of the four E1 peptide-TT immunized rabbits began to shrink. One animal
from this group was free of tumors at the termination of the study. The mean papilloma size of E1 pep-
tide-TT immunized rabbits was signiﬁcantly smaller when compared with that of the three other groups
(P < 0.05, one way ANOVA analysis). It is interesting that E1 peptide-TT vaccination not only stimulated
stronger T cell mediated immune responses but also stronger antibody generations. We conclude that the
location of a TT helper motif tagged at the long peptide vaccine is critical for the outcome of therapeutic
responses to persistent tumors in our HLA-A2.1 transgenic rabbit model.
 2014 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Human papillomaviruses (HPVs) are associated with anogenital
infections and cervical cancer in women [1]. HPV persistent infec-
tions are also detected in other related diseases including vaginal
condylomas, recurrent respiratory papillomas (RRP), common
plantar warts, and anal cancer [2–4]. HPV infections can be cleared
in the majority of healthy people within one year of detection. Host
immunity including innate and adaptive immune responses plays
important roles in eliminating the infected cells because higher
incidences of HPV related diseases and cancers are found in
immunocompromised people such as transplant and HIV-infected
patients [5–7].Two prophylactic vaccines (Gardasil and Cervarix) developed by
Merck and GSK respectively have been implemented in young ado-
lescents [8,9]. These two vaccines, however, have shown no thera-
peutic effects against pre-existing infections [10]. People who have
persistent HPV infections are at risk of developing cancers two dec-
ades later. Therapeutic vaccines that elicit anti-tumor immune
responses in these infected individuals and subsequently eradicate
the infected cells are highly desired [11].
T-cell mediated immune responses are the key players for
tumor regression in patients. Increasing evidence indicates that
both CD4+ T helper and functional CD8+ T cells are required for
effective tumor control [12,13]. Therefore, stimulating both CD4+
helper T cells and functional CD8+ T cells are the key to designing
successful T cell targeted vaccines for persistent infections [13].
Previous studies have demonstrated that control of several chronic
CMV, EBV, and HCV infections require both virus-speciﬁc CD4+
Th1-cells and CD8+ T cells [14,15]. The lack of functional CD4+ T
cell immunity against several HPV early genes such as E6 and E7
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ered one of the major reasons for persistence of the disease
[5,16,17]. Therefore, combinations of CD4+ Th1 cells and speciﬁc
strong CD8 T cell responses are essential for successful therapeutic
responses in HPV infected patients [18,19].
The Cottontail rabbit papillomavirus (CRPV) rabbit model has
played a pivotal role in the development of the two existing pro-
phylactic vaccines [20,21]. HPV was not linked to cervical cancer
until deﬁnitive evidence was found by ground breaking studies
from Dr. Zur Hausen’s group in early 1980s [22]. HPV does not
infect any laboratory animals because of the strict species-speciﬁc
restrictions of these viruses. Therefore, it is not possible to directly
test HPV vaccines against HPV infections experimentally [23,24].
CRPV infection shares many HPV disease properties including per-
sistent infections that can progress to cancer. Previous studies have
shown that vaccination with the non-structural early antigens E1,
E2, E6, E7 and E8 prevent progression of CRPV-induced epithelial
lesions and may even induce regression of CRPV-induced carcino-
mas [25–27]. Clinical trials based on the ﬁndings from animal PV
models have been conducted in humans [28]. At the same time,
novel strategies to stimulate strong therapeutic immune responses
are being continuously explored. One such strategy includes long-
peptide vaccines consisting of peptides that overlap and span the
entire sequence of papillomavirus E6 and E7 proteins. These pep-
tide vaccines have shown promising results in both preclinical ani-
mal models and clinical trials [29,30]. The long peptide vaccines
induced strong CD4+ and CD8+ T-cell immunity in immunized
hosts [31,32].
In this study, we tested long-peptide vaccines in our recently
established CRPV/HLA-A2.1 transgenic rabbit model system [33].
The CRPV/HLA-A2.1 transgenic rabbit model has been used to test
DNA and short peptide vaccines against HLA-A2.1 restricted
epitopes from CRPV, HPV16 and HSV antigens [34] (and unpub-
lished observations). We have veriﬁed HLA-A2.1 restricted targets
from CRPV E1 for both prophylactic and therapeutic T-cell bases
vaccines [35]. Two of these CRPVE1 epitopes (E1/149–157 and
E1/161–169) are adjacent to each other in E1 and we designed a
long peptide vaccine containing a TT helper motif and both these
two epitopes to test therapeutic potential in persistently infected
transgenic rabbits.Materials and methods
Rabbits, viral DNA infection and tumor measurement
HLA-A2.1 transgenic outbred rabbits were maintained in our
animal facility [33]. Sixteen HLA-A2.1 transgenic rabbits (average
weight 4 kg, N = 4/per group) were used for this study. The exper-
iment was conducted following IACUC approval from Pennsylvania
State University College of Medicine. The rabbits were challenged
with wild type CRPV at four back skin sites as described previously
[36]. 5 lg DNA was used for each challenge site. The papillomas
became evident approximately 3–4 weeks after challenge and
were measured in three dimensions (length width  height)
and recorded weekly. Tumor size was calculated based on the geo-
metric volume of each papilloma. The same investigator performed
the measurements throughout the study.HLA-A2.1 expression levels on different cell surfaces
HLA-A2.1 expression on both skin tissues (ear) and spleen cells
were tested by either immunohistochemistry or ﬂow cytometry as
described previously [33]. Positivity of skin cells were graded as
minimum of ‘‘+’’ to maximum of ‘‘++++’’ according to microscopic
visual evaluation. The percentage (%) of A2 positive cells werecalculated automatically based on cells staining stronger than M1
from ﬂow cytometry proﬁles from peripheral blood mononuclear
cells.
Peptides and vaccination
Peptides
Three of the four peptides were synthesized by ChinaPeptides
Co., Ltd. (Shanghai, China). The purity of peptides was over 85%.
Peptide 1 (TT-E1 peptide): QYIKANSKFIGITELILNANTARVKHLLLFR-
QAHSVSFS; peptide 2 (E1 peptide): ILNANTARVKHLLLFRQAHSVSFS
(CRPVE1/149–172); peptide 3 (E1 peptide-TT): ILNANTARVKHLLL-
FRQAHSVSFSQYIKANSKFIGITEL and peptide 4 (TT-control peptide):
QYIKANSKFIGITELLLMGTLGIV (Synthesized in the core facility of
Hershey Medical Center). The underlined amino acid residues
represent the Tetanus Toxin helper motif. Peptides 1–3 contained
CRPVE1/141–172 with two HLA-A2.1 restricted epitopes
(E1/149–157 and E1/161–169) that were demonstrated to be pro-
tective and/or therapeutic in previous studies using DNA-based
vaccines [37]. Peptide 4 contained a HLA-A2.1 restricted epitope
(HPV16E7/82–90) and was used as control for peptide 1–3.
Vaccination
Sixteen HLA-A2.1 outbred transgenic rabbits were divided into
four groups (N = 4/per group). For each vaccination, one hundred
micrograms of each peptide was mixed with phosphate buffered
saline (PBS) in 0.1% DMSO to a ﬁnal volume of approximately
300 ll for each rabbit. The concentration of peptide used was
based on the initial studies demonstrating efﬁcacy [29]. An
emulsion was made with peptide (100 lg) and Montanide ISA 51
(SEPPIC, 1:1, Vol/Vol) and 600 ll was injected intramuscularly in
the hind leg for a total of four times at a two-week interval.
Detection of peptide-speciﬁc antibodies in sera
Sera from each rabbit were collected at the termination of the
experiment and tested by ELISA for peptide speciﬁc antibodies. 1
microgram peptide/per well was used to coat a 96 well plate
(50 lM sodium carbonate, pH9.6) at 37 C overnight. Triplicate
wells were tested for each serum sample. Multiple negative con-
trols were used including second antibody alone, PBS-coated wells
and pre-immune sera for all rabbits. The plate was blocked with
PBS, 2% BSA at room temperature for 1 h, incubated with 1:100
dilution of sera from each rabbit followed by incubation with goat
anti-rabbit IgG-AP (1:2000, SouthernBiotech) for 1 h at room tem-
perature. After washing, the plate was incubated with 100 ll/each
well 1% 4-nitrophenyl phosphate disodium salt hexahydrate tablet
(Sigma) in alkaline phosphate substrate buffer (pH9.5). Color
development was measured at 450 nm using a microplate reader
(Thermolabsystems). The mean and standard error of the OD
values of triplicates from each sample were calculated automati-
cally and graphs were generated with SigmaPlot 11.2 software.
Tetramer binding assay
Spleen cells from all rabbits were harvested at the termination
of the experiment. 0.5106 suspending spleen cells from each rabbit
were washed with RPMI1640 medium and cultured in RPMI1640
with 5% autologous serum together with human recombinant IL-
2 (5–10 U/ml) as described previously [38]. After two in vitro stim-
ulations with autologous cells pulsed with corresponding peptide,
the bulk CTLs were analyzed with corresponding tetramers (gener-
ously prepared by the NIH tetramer facility). The tetramer positive
CD8 T cells were gated and calculated automatically with cytome-
try analysis software in the core facility of Pennsylvania State
University College of Medicine.
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Two of the four tumors from each animal from all four groups
were harvested at the termination of the experiment. The tumor
tissues were ﬁxed in 10% formalin and processed for hematoxylin
and eosin staining as described previously [39]. The slides were
examined under the microscope and the digital images of each
sample were taken for further analysis. The approximate inﬁltrated
lymphocytes were counted and recorded. The cell number less
than 10 was considered negative (), more than 10 was considered
positive (+).
Immunohistochemistry
Frozen tumor tissues harvested at the termination of the
experiment were examined for CD4 and CD8+ T cell inﬁltrates.
Anti-rabbit CD8 (Antigenix American, Cat#MRB8020) and CD4
(Spring Valley laboratory, MD) monoclonal antibody was diluted
to 1:20 for immunostaining as described previously [33]. The posi-
tive CD4 and CD8 T cells were counted and recorded accordingly.Results
HLA-A2.1 expression levels on ear tissues and spleen cells
We tested HLA-A2.1 expression levels on both rabbit ear skin
and spleen cells by either immunohistochemistry or ﬂow cytome-
try (Table 1). The expression levels on ear skin was evaluated and
graded following microscopic examination (Table 1, Supplemental
Fig. 1A). The animals were assigned into different groups based by
balancing gender, birth date as well as A2 expression levels at their
ear skins. No signiﬁcant difference in A2 expression levels on
spleen cells was found among the animals from the four groups
in the experiment (Supplemental Fig. 1B, P > 0.05, one way ANOVA
analysis).
Antibody generation in long-peptide immunized animals
The long peptides contain two HLA-A2.1 restricted epitopes
(CRPVE1/149–157 and CRPVE1/161–169) and/or a TT helper motif.
Serum samples collected at the termination of the experiment
were tested for antibodies against each long peptide as well as to
the CD8 epitopes and the TT helper peptide. All rabbits generated
strong antibody responses against their immunizing long peptideTable 1
HLA-A2.1 expression levels on spleen cells and ear skin tissues by ﬂow cytometry and im
Group (vaccine) Rabbit ID HL
Pos
Group 1 (TT-E1 peptide) 3206 56.
3219 30.
2914 38.
3214 37.
Group 2 (E1 peptide) 3207 32.
3222 56.
2916 28.
3216 31.
Group 3 (E1 peptide-TT) 3210 54.
3223 57.
2917 52.
3217 36.
Group 4 (TT-control) 3211 46.
3224 73.
2918 52.
3218 44.
* Grading of A2 positivity by microscope based on visual inspection. ‘‘+’’ to ‘‘+++’’ rep(Fig. 1A). Cross-reactive antibodies against other peptides were
also detected in some animals. For example, serum from TT-E1
peptide immunized rabbits also generated antibodies against TT-
control peptide while serum from peptide and E1 peptide-TT
immunized animals generated antibodies to the E1 epitope but
not against the TT-E1 peptide. Sera from TT-control peptide immu-
nized animals did not show any cross-reactivity to other E1 pep-
tides (Fig. 1A).
Antibodies against individual epitopes were also detected in the
animals fromvaccinated groups (Fig. 1B). Interestingly, rabbits from
E1 peptide-TT and peptide immunized groups not only generated
stronger antibodies against one of the epitopes (CRPVE1/149–157)
but also to the TT helper peptide. Animals from the three other
groups failed to generate antibodies against any of the E1 peptides
(Fig. 1B).More tetramer positive cells were found in E1 peptide-TT helper
immunized rabbits
To examine whether epitope-speciﬁc T cells were generated in
these long peptide immunized animals, we tested the rabbit spleen
cells after two in vitro stimulationswith tetramers speciﬁc for either
CRVPE1/161–169 or CRPVE1/149–157(Fig. 2A and B). Signiﬁcantly
more tetramer speciﬁc CD8+ T cells to both HLA-A2.1 restricted epi-
topes were found in E1 peptide-TT helper immunized rabbits when
compared with the control group (P < 0.05, one way ANOVA analy-
sis). More tetramer speciﬁc CD8+ T cells were also found in the two
tested groups but were not signiﬁcantly different when compared
with the control group (P < 0.05, one way ANOVA analysis).Tumor regression was found in rabbits immunized with E1 peptide-TT
Rabbits were immunized with long peptide vaccines at 3 weeks
after viral DNA infection. Tumor outgrowth was recorded as shown
in Fig. 3. No signiﬁcant difference in papilloma size was found
among the four groups until week 9 (P > 0.05, one way ANOVA
analysis). At the fourth immunization time point (week 9), tumors
from two out of four animals in the E1 peptide-TT immunized
group regressed or signiﬁcantly reduced in size. The average tumor
size of E1 peptide-TT immunized rabbits was signiﬁcantly smaller
when compared with the other three groups (P < 0.05, one way
ANOVA analysis). No signiﬁcant difference in papilloma size was
found among the other three groups (P > 0.05, one way ANOVA
analysis).munohistochemistry, respectively.
A-A2.1
itive cells on spleen cells (M1%) Positivity on ear tissue*
40 ++/+++
02 +/++
49 ++
52 ++
51 ++/+++
70 +++
15 ++
82 ++
19 ++
14 +/++
28 ++/+++
48 +/++
06 +/++
40 ++
70 +/++
91 +/++
resents from weak to strong A2 staining (as shown in Supplemental Fig. 1).
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Fig. 1. Triplicates were set up for each serum sample as described in the Methods section. Serum samples from rabbits immunized with TT-peptide (white), peptide (dark
gray), peptide-TT (gray) or TT-control peptide (dark) were tested for antibody generation against each peptide. (A) Animals from each group responded to their immunized
peptide strongly. (B) Animals from peptide-TT immunized group also generated detectable antibodies to one of the CD8 epitopes (CRPVE1/149–157) and the TT helper motif.
No strong antibody response was found in other groups.
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under regression
The tumors were examined by H&E staining. A large number of
lymphocytes was found in one of the tumor sites that was undergo-
ing regression from the E1 peptide-TT immunized group (Fig. 4A).
For the persistent tumors, very limited numbers of inﬁltrates were
found (Fig. 4B). Several tumors from the control group showed a
malignant histology again with limited lymphocyte inﬁltration
(Fig. 4C). Approximate number of lymphocyte inﬁltration at corre-
sponding tumor sites from each group were summarized in Table 2.
The number that was less than 10 was considered negative ().
To characterize which cell populations were present in these
inﬁltrates, the tumor tissues were further examined with anti-rab-
bit CD8 and CD4 monoclonal antibodies. Positive cells were
counted under microscope (cell numbers/ﬁeld). A population of
CD8 T cells was found in the tumor sites containing large numbers
of inﬁltrating lymphocytes (about 60 cells/ﬁeld) (Fig. 5B). Minimal
CD8+ T cells were found in persistent tumors (about 14 cells/ﬁeld,
Fig. 5C). Interestingly, most of these CD8+ T cells were located
along the basal layer of the tumor tissue. A large population of
CD4+ T cells (>1000/ﬁeld) was also identiﬁed in these inﬁltrates
at the base of tumors (Fig. 5E) and minimal numbers of CD4+ Tcells (about 36 cells/ﬁeld) were found in persistent tumors
(Fig. 5F).
Discussion
This study reported therapeutic immunization by long peptides
that contained two HLA-A2.1 restricted epitopes and a universal TT
helper motif. Our results demonstrated unexpectedly, that the
location of the TT helper motif played a critical role in the outcome
of the therapeutic vaccination. Speciﬁcally, TT-helper motif at the
N-terminus did not induce any therapeutic response and may in
fact have worsened the therapeutic effect in our transgenic rabbits.
In contrast, the TT helper motif at the carboxyl-terminus provided
a strong therapeutic effect by reducing tumor size and triggering
regression in some rabbits.
Long peptide vaccines have been reported to successfully
induce tumor regression in the CRPV/rabbit model as well as in
clinical trials [18]. The investigators used high doses of pooled
overlapping long peptides that covered E6 and E7 of CRPV for the
preclinical therapeutic vaccination and then the same strategy
for HPV therapeutic vaccine clinical trials [40]. Although this
vaccine strategy has promise, high doses of long peptides in such
vaccines may trigger high levels of CD4 T cell-mediated cytokine
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Fig. 1 (continued)
Tetramer binding for CRPVE1/149-157
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Fig. 2. Tetramer positive CD8+ T cells after in vitro stimulation with two HLA-A2.1 restricted epitopes (A) CRPVE1/149–157 and (B) CRPVE1/161–169. Signiﬁcantly more
tetramer positive CD8+ T cells were found in E1 peptide-TT immunized rabbits when compared with those in the control group (P < 0.05, one way ANOVA analysis). Increased
numbers of tetramer binding cells were found in the other two long peptide vaccinated groups when compared to the control group but the difference was not signiﬁcant
(P > 0.05, one way ANOVA analysis).
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Fig. 3. Tumor outgrowth after viral DNA infection and long peptide immunizations
(arrows indicate the four immunization times: week 3, 5, 7 and 9 post infection).
Signiﬁcantly smaller papillomas induced by wild type CRPV infection were found in
E1 peptide-TT immunized animals when compared with those from the other three
groups after week 9 (P < 0.05, one way ANOVA analysis). No signiﬁcant difference
was found among the other three groups at all the time points (P > 0.05, one way
ANOVA analysis).
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Therefore, improved design and preclinical testing of long peptide
vaccines would be beneﬁcial.Fig. 4. H&E staining of tumors harvested at the termination of the experiment. (A) H
immunized rabbits; (B) low lymphocytic inﬁltration was found in persistent tumors as sh
cancer) was found from one (3211) of the control group rabbits (10).
Table 2
Summary of lymphocytic inﬁltration in tumor tissues (under 20 object lens).
Group (vaccine) Rabbit ID Approxim
Tumor s
Group 1 (TT-E1 peptide) 3206 (9)
3219 (10)
2914 +(30)
3214 (4)
Group 2 (E1 peptide) 3207 (8)
3222 +(47)
2916 (9)
3216 (8)
Group 3 (E1 peptide-TT) 3210 (8)
3223 +(>100)
2917 NA
3217 –(10)
Group 4 (TT-control) 3211 (10)
3224 (9)
2918 (10)
3218 +(20)
NA— the sites without tumors. Lymphocytes inﬁltration was graded from negative ( w
Fig. 4A).
a Early cancer was shown in Fig. 4B by H&E histology staining.Our HLA-A2.1 transgenic rabbit model has been established to
test therapeutic strategies against HPV related antigens [38]. How-
ever, most of the proof-of-concept studies were conducted with
CRPV which induces a natural infection and tumor growth in rab-
bits [35,37,42]. We recently showed that a multivalent DNA vac-
cine containing ﬁve HLA-A2.1 restricted epitopes from CRPV E1
gene provided not only complete protective immunity but also
strong therapeutic immunity in the HLA-A2.1 transgenic rabbits
[35]. We further conﬁrmed that all ﬁve epitopes could provide pro-
tective immunity while two of these ﬁve epitopes could also be
potentially therapeutic [37]. Making use of the location of two
HLA-A2.1 restricted epitopes from CRPVE1 (149–157 and 161–
169), we designed a long peptide vaccine that overlapped these
two naturally existing CD8 epitopes. We have included a TT helper
motif at the N-terminus of the epitopes to augment immune
responses in our previous DNA vaccination studies and demon-
strated that this motif improved immune responses when mixed
with short peptides [42]. Therefore, we decided to include the TT
helper motif in the present study to preclude the possibility that
the long peptide lacks CD4 epitopes. Importantly, we did not know
whether the location of the TT-helper motif could impact the out-
come of the therapy, so we designed two long peptides with the TT
helper at either the N-terminus or the carboxyl-terminus together
with a long peptide with no TT-helper motif. Surprisingly, the long
peptide with the TT helper motif at the carboxyl-terminus rather
than at the N-terminus showed much stronger therapeutic effects
in our HLA-A2.1 transgenic rabbits. The long peptide without the
TT-helper motif generated only marginal therapeutic responsesigh lymphocytic inﬁltration was found in one (3223) of the E1 peptide-TT helper
own here from one (3224) of the control group (10); (C) a malignant tumor (early
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Fig. 5. Immunohistological detection of CD8+ (A–C) and CD4+ T (D–F) cells at the sites of lymphocytic inﬁltration. (A and D) Negative control omitting monoclonal antibody
against rabbit CD8 and CD4 during the staining; (B and E) A population of CD8+ and CD4+ T cells (red) were found around the basal layer of the tumor (shown by arrows) that
showed high levels of lymphocytic inﬁltration as shown in Fig. 4A (10); (C and F) low numbers of CD8+ and CD4+ T cells were found in the persistent tumors that had
limited lymphocytic inﬁltration (10), respectively. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
140 J. Hu et al. / Trials in Vaccinology 3 (2014) 134–142in rabbits. These ﬁndings indicate that the TT-helper motif is
required for an effective therapy for long peptide vaccine and that
the location of TT-helper motif greatly impacts therapeutic
outcomes.
We analyzed both humoral and cellular immune responses
stimulated by these long peptide immunizations in order to deter-
mine why the E1 peptide-TT induced a stronger therapeutic effect.
One explanation might be that this latter peptide is more stable
than the other two. A previous study demonstrated that the stabil-
ity of antigen played an important role in DNA vaccination [43]. If
the E1 peptide-TT was a more stable antigen, then wewould expect
a much stronger immune response and this was what we observed.
Long peptides are proven effective antigens for antibody
generation [29]. We found that all the long peptides successfully
produced strong antibody responses to the corresponding immu-
nogens. The TT-E1 peptide also generated a cross-reactive antibody
against the control vaccine which contains a TT helper motif at the
N-terminus. Interestingly, all the rabbits in E1 peptide-TT group
also generated antibodies against one of the CD8 T cell epitopes
(CRPVE1/149–157) as well as the TT helper motif. This may indi-
cate this long peptide was properly processed in vivo as well.
Our previous study found that CRPVE1/149–157 epitope vaccine
was both protective and therapeutic [37]. Overall, animals
vaccinated with the E1 peptide-TT showed the highest level of
antibody generation when compared with the other two long
peptides. Although the antibody responses have not been found
to correlate with the therapeutic outcome because humoral immu-
nity was reported to play a minimal role in tumor clearance, the
anti-peptide antibodies may have played a role in improved anti-
gen presentation pathways for cell-mediated immune responses
as antigen–antibody complexes in the later vaccinations.
We further examined the role of T-cell mediated immune
responses in the outcome of therapy in these rabbits. Because
the in vitro culture system is not optimal for rabbit T cells, we only
detected small populations of epitope speciﬁc T cells. Nevertheless,
we were able to detect statistically signiﬁcantly more tetramerbinding CD8 T cells for both epitopes from E1 peptide-TT
immunized animals, and this ﬁnding correlated with best
therapeutic outcome. In vitro T cell stimulation assay was designed
to test the systematic immune responses. For our model, the local
immune responses might play a more important role in eliminat-
ing the tumor cells and therefore could be more appropriate indi-
cators. Therefore, we analyzed the local immunity by both H&E
staining and immunohistochemistry assay. Increased lymphocytic
inﬁltration was detected in the small tumor tissues from E1 pep-
tide-TT immunized animals by H&E staining. A portion of these
inﬁltrating lymphocytes were further conﬁrmed as CD8+ T cells.
Interestingly, these CD8+ T cells were located at the basal layer
of the papillomas which make them available to attack the virally
infected cells at the base of the papilloma. In control persistent
tumors, very few CD8+ T cells were found at the same location
demonstrating their likely role in eliminating infected virally
infected cells. A similar pattern was found for CD4+ T cells in these
tumor tissues. Therefore, stronger T cell-mediated immune
responses elicited in E1 peptide-TT helper immunized animals
contributed to the strong therapeutic effect we observed.
One of the animals in the E1 peptide-TT group, however, failed
to respond to the treatment although this animal showed similar
in vitro humoral and cellular immune responses. No lymphocytic
inﬁltration was identiﬁed in the tumor tissues. This result reso-
nates with ﬁndings in human studies in which populations are het-
erogenic and patient responses stratify into responders and non-
responders. Given the fact that no human papillomavirus infection
model is available, this model system will shed light on a better
understanding of human papillomavirus infection in heterogenic
human populations.
It is challenging to treat existing large tumors through immuni-
zation [44]. Improved preventive and therapeutic endpoints have
been found in previous studies using combinations of topical treat-
ments and DNA vaccination [45], peptide and DNA vaccines [42],
DNA vaccines based on recombinant VSV [44,46] and combinations
of multiple antigens [26,35,47]. Adjuvants such as Toll-like
J. Hu et al. / Trials in Vaccinology 3 (2014) 134–142 141receptor agonists and CpG have been included in tumor therapeu-
tic studies to enhance the speciﬁc adaptive immunity in hosts
[48,49]. Recently, we tested siRNA targeted anti-viral therapy in
our rabbit model system and showed promising preliminary
ﬁndings (unpublished observations). We believe that combination
therapeutic strategies that include immunotherapeutic approaches
will be the optimal way to cure papillomavirus induced tumors.Acknowledgement
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